Quick Answer
Voyager Therapeutics, Inc. reported Diluted EPS of $2.04 per share (loss) for fiscal year 2025.
Voyager Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.04 | -80.5% |
| 2024 | -$1.13 | -138.0% |
| 2023 | $2.97 | +345.5% |
| 2022 | -$1.21 | +36.0% |
| 2021 | -$1.89 | -292.9% |
| 2020 | $0.98 | +181.0% |
| 2019 | -$1.21 | +56.0% |
| 2018 | -$2.75 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.47 | -193.7% | +17.5% |
| June 30, 2025 | -$0.57 | -216.7% | -7.5% |
| March 31, 2025 | -$0.53 | -165.0% | -231.2% |
| September 30, 2024 | -$0.16 | +72.9% | +11.1% |
| June 30, 2024 | -$0.18 | +64.7% | +10.0% |
| March 31, 2024 | -$0.20 | -106.8% | +66.1% |
| September 30, 2023 | -$0.59 | -231.1% | -15.7% |
| June 30, 2023 | -$0.51 | -2.0% | -117.3% |
- Voyager Therapeutics, Inc. showed a decrease of -80.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2018–2025 period, Voyager Therapeutics, Inc.’s diluted eps has grown by 25.8% (from $2.75 per share (loss) to $2.04 per share (loss)).
- The most recent figure is from Voyager Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: